Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging

Melissa N. McCracken,1 Dimitrios N. Vatakis,2,3,4 Dhaval Dixit,2,3,4 Jami McLaughlin,5 Jerome A. Zack,2,3,4,5,6 and Owen N. Witte1,4,5,6,7,8

1Department of Molecular and Medical Pharmacology and 2Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.
3UCLA AIDS Institute, 4Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and 5Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California, USA.
6Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, UCLA, Los Angeles, California, USA. 7Molecular Biology Institute and 8Howard Hughes Medical Institute, UCLA, Los Angeles, California, USA.

Adoptive transfer of tumor-reactive T cells can successfully reduce tumor burden; however, in rare cases, lethal on-target/off-tumor effects have been reported. A noninvasive method to track engineered cells with high sensitivity and resolution would allow observation of correct cell homing and/or identification of dangerous off-target locations in preclinical and clinical applications. Human deoxycytidine kinase triple mutant (hdCK3mut) is a nonimmunogenic PET reporter that was previously shown to be an effective tool to monitor whole-body hematopoiesis. Here, we engineered a construct in which hdCK3mut is coexpressed with the anti-melanoma T cell receptor F5, introduced this construct into human CD34 cells or PBMCs, and evaluated this approach in multiple immunotherapy models. Expression of hdCK3mut allowed engrafted cells to be visualized within recipient bone marrow, while accumulation of [18F]-L-FMAU in hdCK3mut-expressing T cells permitted detection of intratumoral homing. Animals that received T cells coexpressing hdCK3mut and the anti-melanoma T cell receptor had demonstrably higher signals in HLA-matched tumors compared with those in animals that received cells solely expressing hdCK3mut. Engineered T cells caused cytotoxicity in HLA/antigen-matched tumors and induced IFN-γ production and activation. Moreover, hdCK3mut permitted simultaneous monitoring of engraftment and tumor infiltration, without affecting T cell function. Our findings suggest that hdCK3mut reporter imaging can be applied in clinical immunotherapies for whole-body detection of engineered cell locations.

Introduction
Adoptive cellular immunotherapy provides an alternative cancer treatment to traditional chemotherapies and antibody-based therapies (1, 2). Patient-specific lymphocytes are isolated via blood or tumor resections, expanded by cytokine stimulation, and, in some cases, engineered to express transgenic T cell receptors (TCRs) or chimeric antigen receptors (CARs) that specifically recognize the tumor (3–5). Infused lymphocytes are required to successfully home to the target tumors and mediate cytotoxicity (1, 5).

The large expansion ex vivo prior to infusion can cause defects in T cell function (6, 7). In most clinical trials, engineered T cells are almost undetectable in the peripheral blood after approximately 1 month (8–10). To increase the therapeutic window, investigators have proposed to use engineered hematopoietic stem cells (HSCs) to allow for a constant source of naive engineered T cells in vivo (11). Expansion of patient peripheral blood mononuclear cells (PBMCs) can alter the tumor-homing function, reducing the efficacy of infused cells (12). Nonspecific expansion of PBMCs or TCR mismatching when cells are engineered to express a specific TCR can increase the number of alloreactive T cells, possibly causing issues of autoimmunity and graft-versus-host disease (13–15). In the case of engineered TCRs or CARs, these cells have the potential to recognize on-target/off-tumor sites of proper epitope display or of epitopes similar to the target (4, 13). Off-target toxicity can be lethal and reinforces the need for improved preclinical and clinical methods of determining nontumor localization (16).

Peripheral blood analysis is a fast, simple, and routine method for monitoring transplanted lymphocytes. Cells isolated from blood can define quantity, phenotype, and cytokine levels. The limitation to peripheral blood sampling is the lack of information regarding lymphocyte location in sites outside the circulation. Noninvasive, whole-body measurements are needed to determine additional sites of transplanted cells in vivo (17). Reporter imaging by PET provides a 3D, highly sensitive method to detect transplanted cell locations for both preclinical and clinical therapies (17, 18). Expression of a PET reporter gene in specific cell populations allows investigators to serially monitor the initial transplant and subsequent tumor infiltration or off-target locations of engineered cells (19, 20).

Herpes simplex virus thymidine kinase (HSV-TK) was the first PET reporter gene translated into clinical use (21, 22). The specificity of HSV-TK for its radiolabeled probe 9-[(4-[(18F]fluoromethyl)butyl]guanine ([18F]FHBG) allows for precise detection of cells expressing this PET reporter gene. HSV-TK has had limited clinical utility, due to the immunogenicity and clearance of lymphocytes expressing the PET reporter gene (23, 24). Most patients will be seropositive for herpes simplex virus prior to transfusion of labeled cells, indicating an adaptive immune memory response of B cells from prior exposure to herpes sim-
hdCK3mut is a mutant deoxycytidine kinase and could potentially cause toxicity during immune cell activation by changing cellular nucleotide pools. In ADA-SCID, a buildup of deoxyadenosine triphosphate causes T cell toxicity (30). In addition, mice with a genetic loss of deoxycytidine kinase have a dramatic reduction in both T and B cells, which was found to be due to a replication stress defect due to the imbalanced nucleotide pools (31).

To test whether the hdCK3mut PET reporter affects T cell function, we used two models of adoptive immunotherapy: (a) transfusion of reporter and TCR-engineered PBMCs into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) tumor-bearing recipients (these recipients had a rapid decline in peripheral T cells) and (b) a previously described humanized mouse model of HSC adoptive immunotherapy that allows for continuous development of engineered T cells (32). Human HSCs are engineered for TCR expression ex vivo and developed into cytotoxic T cells in vivo. hdCK3mut alone or hdCK3mut coexpressed with the F5 TCR reactive against melanoma antigen recognized by T cells 1 (MART-1) was used as a model to demonstrate the utility, safety, and the biologically inert effect of hdCK3mut on T cell function.

We demonstrate that hdCK3mut can be used to monitor adoptive cell therapy (ACT), using engineered TCRs in human PBMCs and HSCs. Engineered PBMCs expressing hdCK3mut retained plex virus (25). Previous clinical applications found that labeled cells expressing HSV-TK were cleared quickly due to a memory CD8 T cell response (23, 24). This suggests that HSV-TK will have limited utility for monitoring transplanted cell populations long term.

The nonimmunogenic human-based PET reporter gene human deoxycytidine kinase triple mutant (hdCK3mut) was developed as an alternative to other human PET reporters and HSV-TK (20). hdCK3mut is smaller than HSV-TK, which is beneficial in constructing therapeutic vectors that have size limitations. hdCK3mut is more sensitive than alternative PET reporters, allowing for increased signal at sites expressing hdCK3mut (26). The engineered substrate affinity of hdCK3mut is toward thymidine analogs (27, 28), while HSV-TK is engineered toward acycloguanosine substrates (29). In some chemotherapy and bone marrow transplant regimens, a continuous administration of acycloguanosine compounds is given as prophylactic antivirals, limiting the use of HSV-TK in these settings (18, 25). The use of hdCK3mut as a PET reporter would allow for the continuous treatment with such antivirals.

We previously showed that hdCK3mut can visualize hematopoietic engraftment after HSC transplantation and found expression of hdCK3mut to be nondeleterious to cell engraftment, expansion, and development (20).

hdCK3mut is a mutant deoxycytidine kinase and could potentially cause toxicity during immune cell activation by changing cellular nucleotide pools. In ADA-SCID, a buildup of deoxyadenosine triphosphate causes T cell toxicity (30). In addition, mice with a genetic loss of deoxycytidine kinase have a dramatic reduction in both T and B cells, which was found to be due to a replication stress defect due to the imbalanced nucleotide pools (31).

To test whether the hdCK3mut PET reporter affects T cell function, we used two models of adoptive immunotherapy: (a) transfusion of reporter and TCR-engineered PBMCs into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) tumor-bearing recipients (these recipients had a rapid decline in peripheral T cells) and (b) a previously described humanized mouse model of HSC adoptive immunotherapy that allows for continuous development of engineered T cells (32). Human HSCs are engineered for TCR expression ex vivo and developed into cytotoxic T cells in vivo. hdCK3mut alone or hdCK3mut coexpressed with the F5 TCR reactive against melanoma antigen recognized by T cells 1 (MART-1) was used as a model to demonstrate the utility, safety, and the biologically inert effect of hdCK3mut on T cell function.

We demonstrate that hdCK3mut can be used to monitor adoptive cell therapy (ACT), using engineered TCRs in human PBMCs and HSCs. Engineered PBMCs expressing hdCK3mut retained
equivalent cytotoxicity, activation, and cytokine production. ACT with PBMCs demonstrated that hdCK3mut-expressing PBMCs could be detected intratumor with PET reporter imaging. For the HSC immunotherapy, functional splenocytes were isolated and stimulated ex vivo at the experimental endpoint. These isolated cytotoxic T lymphocytes were capable of IFN-γ production after stimulation. F5 T cells were activated and detected by surface activation markers in flow cytometry after antigen presentation by coculturing MART-1–expressing artificial antigen-presenting cells (aAPCs). In vivo, the antigen-positive HLA-matched tumors in animals receiving F5 TCR with hdCK3mut-transduced (F5/hdCK3mut-transduced) HSCs had increased accumulation of 2′-deoxy-2′-[18F]-fluoro-5-methyl-1-β-L-arabinofuranosyluracil ([18F]-L-FMAU) in comparison to HLA-mismatched tumors. HLA-matched tumors from the animals that received F5/hdCK3mut had an increase in [18F]-L-FMAU accumulation due to the infiltrated antigen-specific cytotoxic T cells in comparison to the hdCK3mut recipients. F5/hdCK3mut animals had increased cell death within the tumor. In this study, we demonstrate that hdCK3mut provides a safe, nonimmunogenic method for measuring engineered adoptive cell transplant therapy engraftment and tumor infiltration in vivo.

Results

Expression of hdCK3mut does not affect T cell function in vitro. HLA-A02 human PBMCs were transduced to express F5, F5/hdCK3mut, or hdCK3mut. We tested whether the coexpression of hdCK3mut would alter the engineered T cell function.

To test whether cytokine production is altered, PBMCs were treated with phorbol 12-myristate 13-acetate (PMA) and ionomycin for T cell activation (Figure 1, A and B). CD8 cells were capable of IFN-γ production, and no difference in the quantity of cytokine-producing cells was observed between groups (Figure 1C). CD4 cells engineered to express the MHC class I–restricted F5 TCR have been previously described to exhibit a Th1 phenotype with increased IFN-γ production (33). CD4 cells expressing either F5 or F5/hdCK3mut produced equivalent IFN-γ when stimulated by PMA/ionomycin (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI77326DS1).

PBMCs were then cocultured with aAPCs for 72 hours to validate that F5/hdCK3mut cells could be activated by the antigen MART-1, with minimal activation in aAPCs expressing hdCK3mut. F5 and F5/hdCK3mut were comparable in T cell activation, as measured by flow cytometry (Supplemental Figure 2).

Figure 2. Visualization of short-term hdCK3mut-transduced PBMC T cell trafficking into M202 tumors. (A) PET imaging of adoptive cell transfer with NSG mice with M202 (HLA-A*0201· MART-1+) tumors receiving 5 × 10^6 PBMCs (40% transduced). PBMCs were transferred on day 0 i.v. with 50,000 IU of IL-2 i.p. (B) [18F]-L-FMAU imaging and quantification was performed on day 1, (C) that for [18F]-FDG was performed on day 2, and (D) that for [18F]-L-FMAU was performed on day 8. Quantification is shown as mean ± SD, n = 3. Peripheral blood on day 9 after ACT for total human CD4, CD8, and F5 engineered cells for (E) F5/hdCK3mut and (F) hdCK3mut.
To test growth potential or loss of engineered T cells, F5 or F5/hdCK3mut T cells were serially cultured for over 2 weeks with aAPCs expressing MART-1 or hdCK3mut. On day 0, 2, 5, 9, 12, and 15, cultures were analyzed for total cell count, phenotype by FACS, and replated with irradiated aAPCs (Supplemental Figure 3A). Total cell counts were consistent between F5 and F5/hdCK3mut (Supplemental Figure 3B). Flow cytometry tracked total CD8 and CD4 cells with no significant difference observed (Supplemental Figure 3, C-E). Tetramer staining for the F5 TCR on CD4 and CD8 cells demonstrated a modest increase in the percentages of F5 T cells in the wells without aAPCs (Supplemental Figure 3, F and G). We confirmed that the expression of either F5 or F5/hdCK3mut caused no reduction in the growth or loss of TCR expression over time in vitro.

When tested in a cell cytotoxicity assay, the cytotoxicity and killing capacity of engineered PBMCs expressing F5/hdCK3mut was indistinguishable from that in those expressing F5 alone. Melanoma cells were prelabeled with a GFP dye and cocultured with PBMCs at a 10:1 effector/target ratio. Dead cells were counted as DAPI+ and GFP+ by flow cytometry (Figure 1D). Significant cytotoxicity was only seen in T cells expressing F5 or F5/hdCK3mut cultured with M202 (HLA-A2.1*MART-1+) tumors and not in those cultured with M207 (HLA-A2.1*MART-1+) or M407 (HLA-A2.1*MART-1) tumors (Figure 1E). These in vitro assays demonstrate that the addition of the hdCK3mut PET reporter gene is inert on T cell function.

Visualization of hdCK3mut-expressing T cells by [18F]-L-FMAU PET after adoptive cell transfer of engineered PBMCs. To test growth potential or loss of engineered T cells, F5 or F5/hdCK3mut T cells were serially cultured for over 2 weeks with aAPCs expressing MART-1 or hdCK3mut. On day 0, 2, 5, 9, 12, and 15, cultures were analyzed for total cell count, phenotype by FACS, and replated with irradiated aAPCs (Supplemental Figure 3A). Total cell counts were consistent between F5 and F5/hdCK3mut (Supplemental Figure 3B). Flow cytometry tracked total CD8 and CD4 cells with no significant difference observed (Supplemental Figure 3, C-E). Tetramer staining for the F5 TCR on CD4 and CD8 cells demonstrated a modest increase in the percentages of F5 T cells in the wells without aAPCs (Supplemental Figure 3, F and G). We confirmed that the expression of either F5 or F5/hdCK3mut caused no reduction in the growth or loss of TCR expression over time in vitro.

When tested in a cell cytotoxicity assay, the cytotoxicity and killing capacity of engineered PBMCs expressing F5/hdCK3mut was indistinguishable from that in those expressing F5 alone. Melanoma cells were prelabeled with a GFP dye and cocultured with PBMCs at a 10:1 effector/target ratio. Dead cells were counted as DAPI+ and GFP+ by flow cytometry (Figure 1D). Significant cytotoxicity was only seen in T cells expressing F5 or F5/hdCK3mut cultured with M202 (HLA-A2.1*MART-1+) tumors and not in those cultured with M207 (HLA-A2.1*MART-1+) or M407 (HLA-A2.1*MART-1) tumors (Figure 1E). These in vitro assays demonstrate that the addition of the hdCK3mut PET reporter gene is inert on T cell function.

Visualization of hdCK3mut-expressing T cells by [18F]-L-FMAU PET after adoptive cell transfer of engineered PBMCs. To test growth potential or loss of engineered T cells, F5 or F5/hdCK3mut T cells were serially cultured for over 2 weeks with aAPCs expressing MART-1 or hdCK3mut. On day 0, 2, 5, 9, 12, and 15, cultures were analyzed for total cell count, phenotype by FACS, and replated with irradiated aAPCs (Supplemental Figure 3A). Total cell counts were consistent between F5 and F5/hdCK3mut (Supplemental Figure 3B). Flow cytometry tracked total CD8 and CD4 cells with no significant difference observed (Supplemental Figure 3, C-E). Tetramer staining for the F5 TCR on CD4 and CD8 cells demonstrated a modest increase in the percentages of F5 T cells in the wells without aAPCs (Supplemental Figure 3, F and G). We confirmed that the expression of either F5 or F5/hdCK3mut caused no reduction in the growth or loss of TCR expression over time in vitro.

When tested in a cell cytotoxicity assay, the cytotoxicity and killing capacity of engineered PBMCs expressing F5/hdCK3mut was indistinguishable from that in those expressing F5 alone. Melanoma cells were prelabeled with a GFP dye and cocultured with PBMCs at a 10:1 effector/target ratio. Dead cells were counted as DAPI+ and GFP+ by flow cytometry (Figure 1D). Significant cytotoxicity was only seen in T cells expressing F5 or F5/hdCK3mut cultured with M202 (HLA-A2.1*MART-1+) tumors and not in those cultured with M207 (HLA-A2.1*MART-1+) or M407 (HLA-A2.1*MART-1) tumors (Figure 1E). These in vitro assays demonstrate that the addition of the hdCK3mut PET reporter gene is inert on T cell function.

Visualization of hdCK3mut-expressing T cells by [18F]-L-FMAU PET after adoptive cell transfer of engineered PBMCs. To test growth potential or loss of engineered T cells, F5 or F5/hdCK3mut T cells were serially cultured for over 2 weeks with aAPCs expressing MART-1 or hdCK3mut. On day 0, 2, 5, 9, 12, and 15, cultures were analyzed for total cell count, phenotype by FACS, and replated with irradiated aAPCs (Supplemental Figure 3A). Total cell counts were consistent between F5 and F5/hdCK3mut (Supplemental Figure 3B). Flow cytometry tracked total CD8 and CD4 cells with no significant difference observed (Supplemental Figure 3, C-E). Tetramer staining for the F5 TCR on CD4 and CD8 cells demonstrated a modest increase in the percentages of F5 T cells in the wells without aAPCs (Supplemental Figure 3, F and G). We confirmed that the expression of either F5 or F5/hdCK3mut caused no reduction in the growth or loss of TCR expression over time in vitro.

When tested in a cell cytotoxicity assay, the cytotoxicity and killing capacity of engineered PBMCs expressing F5/hdCK3mut was indistinguishable from that in those expressing F5 alone. Melanoma cells were prelabeled with a GFP dye and cocultured with PBMCs at a 10:1 effector/target ratio. Dead cells were counted as DAPI+ and GFP+ by flow cytometry (Figure 1D). Significant cytotoxicity was only seen in T cells expressing F5 or F5/hdCK3mut cultured with M202 (HLA-A2.1*MART-1+) tumors and not in those cultured with M207 (HLA-A2.1*MART-1+) or M407 (HLA-A2.1*MART-1) tumors (Figure 1E). These in vitro assays demonstrate that the addition of the hdCK3mut PET reporter gene is inert on T cell function.

Visualization of hdCK3mut-expressing T cells by [18F]-L-FMAU PET after adoptive cell transfer of engineered PBMCs. To test growth potential or loss of engineered T cells, F5 or F5/hdCK3mut T cells were serially cultured for over 2 weeks with aAPCs expressing MART-1 or hdCK3mut. On day 0, 2, 5, 9, 12, and 15, cultures were analyzed for total cell count, phenotype by FACS, and replated with irradiated aAPCs (Supplemental Figure 3A). Total cell counts were consistent between F5 and F5/hdCK3mut (Supplemental Figure 3B). Flow cytometry tracked total CD8 and CD4 cells with no significant difference observed (Supplemental Figure 3, C-E). Tetramer staining for the F5 TCR on CD4 and CD8 cells demonstrated a modest increase in the percentages of F5 T cells in the wells without aAPCs (Supplemental Figure 3, F and G). We confirmed that the expression of either F5 or F5/hdCK3mut caused no reduction in the growth or loss of TCR expression over time in vitro.

When tested in a cell cytotoxicity assay, the cytotoxicity and killing capacity of engineered PBMCs expressing F5/hdCK3mut was indistinguishable from that in those expressing F5 alone. Melanoma cells were prelabeled with a GFP dye and cocultured with PBMCs at a 10:1 effector/target ratio. Dead cells were counted as DAPI+ and GFP+ by flow cytometry (Figure 1D). Significant cytotoxicity was only seen in T cells expressing F5 or F5/hdCK3mut cultured with M202 (HLA-A2.1*MART-1+) tumors and not in those cultured with M207 (HLA-A2.1*MART-1+) or M407 (HLA-A2.1*MART-1) tumors (Figure 1E). These in vitro assays demonstrate that the addition of the hdCK3mut PET reporter gene is inert on T cell function.
vector and separated into one of three cohorts: CD34 control with no vector transduction, hdCK3mut alone, and the engineered MART-1 F5/hdCK3mut (Figure 3B). These 3 animal cohorts allow for the investigation of the effect of hdCK3mut on T cell development and function in vivo.

Transplanted CD34 cells engraft within the bone marrow and develop into lymphocyte progenitors that home to the thymic graft (34). Only a fraction of the CD34 cells are gene modified and a diverse T cell repertoire will develop in vivo (15, 32, 34). It is possible that the F5-expressing cells may be eliminated by negative selection due to TCR mismatching from endogenous TCR and F5 TCR. Additional human B cells, NK cells, and myeloid cells are developed in the BLT mouse and can express the hdCK3mut PET reporter gene if vector marked. Animals are then tumor challenged 12 weeks after HSC transplant with 2 MART-1–positive melanoma tumors. M202 tumors express HLA A2.1, and M207 is an HLA-mismatched tumor. Engineered T cells can only recognize the MART-1 peptide in an HLA A2.1 MHC class I presentation.

Total engraftment was evaluated at the experimental endpoint by flow cytometry analysis of cells from the spleen. Flow cytometry provided information on total engraftment of human cells in hdCK3mut (Figure 4A) and F5/hdCK3mut (Figure 4B). MART-1 tetramer staining measures the percentage of T cells that are engineered to express the F5 TCR and was seen only in F5/hdCK3mut recipient animals (Figure 4B). Expression of the F5/hdCK3mut or hdCK3mut alone did not affect the human cell engraftment or lineage development. In all cohorts, total human cell engraftment was approximately 50% of the gated lymphocyte compartment from forward scatter and side scatter (Figure 4C). Composition of the human cell engraftment was roughly equivalent for the percentage of CD19, CD33, CD4, and CD8 cells in all treatment cohorts (Figure 4D). The comparable human cell engraftment and development among groups demonstrates that hdCK3mut expression is not deleterious during immune cell development.

hdCK3mut-expressing T cells developed in humanized mice are capable of activation and cytokine secretion. T cells from splenocytes of BLT mice were cultured in low IL-2 and stimulated by PMA/ionomycin or untreated. Intracellular IFN-γ was measured by intracellular flow (Figure 5, A and B). Cytotoxic T cells (CD3, CD8) produced IFN-γ after overnight stimulation indicative of immune cell activation. No difference in the quantity of the total percentage of activated cells in reporter-labeled cells compared with that in untransduced cells was detected (Figure 5C). Production of IFN-γ in CD8 cells demonstrates an activated phenotype, with proper cytotoxic T cell function. Although PMA/ionomycin causes general cell stimulation in T cells, exhausted or developmentally impaired CD8 cells should lack the capability to produce cytokines upon stimulation. T cells expressing hdCK3mut had no impairment in IFN-γ production, which was equivalent to that in the control animals.

F5 TCR T cells expressing hdCK3mut can be activated by aAPCs with MART-1 peptide. K562 cells were used as aAPCs and engineered to express MART-1 or hdCK3mut. Isolated splenocytes were cocultured with aAPCs and low IL-2 for 3 days. Since MART-1 is a self-peptide, we monitored the activation of alloreactive T cells. The upregulation of the surface markers CD25 and CD71 in CD8 cells demonstrates an activated phenotype, with proper cytotoxic T cell function. Although PMA/ionomycin causes general cell stimulation in T cells, exhausted or developmentally impaired CD8 cells should lack the capability to produce cytokines upon stimulation. T cells expressing hdCK3mut had no impairment in IFN-γ production, which was equivalent to that in the control animals.

F5 T cells from the F5/hdCK3mut recipients were activated by the antigen-matched MART-1 aAPCs (Figure 5, D and G). F5 T cells were not activated against the hdCK3mut-expressing aAPCs (Figure 5, E and G). We compared the total activated CD8 cells from F5/hdCK3mut and hdCK3mut animals when cultured with aAPCs expressing hdCK3mut or MART-1 (Figure 5F). A slight increase in the CD25 CD71 expression was seen with F5/hdCK3mut T cells cocultured with MART-1, with
no change seen in the hdCK3mut T cells (Figure 5F). A nonsignificant number of CD8 cells was activated against the aAPCs expressing the hdCK3mut. This indicates that there is not a recurrent population of mature CD8 or memory CD8 cells specific to hdCK3mut.

The activation of engineered F5 T cells when cultured with MART-1 aAPCs was 8-fold higher in comparison to that in F5 T cells when cultured with hdCK3mut aAPCs (Figure 5G). This demonstrates that engineered F5 T cells are capable of antigen-specific activation.

Figure 5. hdCK3mut-expressing T cells developed in vivo are capable of cytokine production and activation. (A) Representative FACS plots of cultures incubated with PMA/ionomycin or (B) untreated. Subgate on CD8 cells showing intracellular IFN-γ by intracellular flow cytometry. IgG isotype was used as a control for background staining. (C) Percentage of CD8 cells that produce IFN-γ, shown as mean ± SD. K562 aAPCs and T cells were cocultured for 72 hours. Representative flow cytometry plots from T cells of F5/hdCK3mut animals cocultured with (D) MART-1-expressing aAPCs or (E) hdCK3mut aAPCs. F5 T cells are shown on the top row, and CD8 T cells are shown on the bottom row. (F) Total activated T cells after 72 hours coculture with aAPCs (CD25+CD71+) for F5/hdCK3mut or hdCK3mut recipients. NS by 1-way ANOVA, shown as mean + SEM (n = 3). (G) Engineered F5 T cell activation with aAPCs (**P < 0.005), shown as mean + SEM (n = 3).
dose per gram [%ID/g]) in the tumor to that in muscle in all animals (Figure 7B, Supplemental Figure 5B, and Supplemental Figure 6B). All tumors from each cohort had similar glycolytic activity, as measured by [18F]-FDG accumulation (nonsignificant by 1-way ANOVA, P = 0.42), indicating that all tumors were engrafted with viable tissue (Supplemental Table 1). The regions of interest (ROIs) drawn from the [18F]-FDG scans were used to identify tumor size and location in the follow-up PET reporter imaging scan.

To determine the relative engraftment and location of the engineered cells, [18F]-L-FMAU PET reporter imaging was performed. [18F]-L-FMAU specifically accumulates in cells expressing hdCK3mut. In both cohorts engineered to express hdCK3mut a constitutive promoter was used, allowing for detection of all cells that are vector marked. The advantage of this approach is that the vector-marked stem, progenitor, and differentiated cells can all be detected with one noninvasive scan. Engraftment of progenitors within the bone marrow of F5/hdCK3mut and hdCK3mut animals can be visualized (Figure 8, A and B). Bone signal was quantified by drawing ROIs around the PET bone signal, with “control bone” being a contralateral region with low/no observable PET signal. Signal was plotted as a fold change over muscle, with [18F]-LFMAU bone signal causing a 2.1-fold increase and control bone causing a 1.2-fold increase in signal over muscle (Figure 8C). Additional sites of engraftment can include the lymph nodes and spleen. No strong spleen signal was observed; signal may be present and weak but is difficult to distinguish based on the high clearance of probe through the kidneys adjacent to the spleen.

Engineered cells can mature into myeloid, B, or T cells in vivo. Only cells that are CD3 positive will express the engineered F5 TCR. It is possible that signal may be observed in additional sites, including M207 tumors, due to the infiltration of nonspecific immune cells. To validate that the signal seen within M202 tumors is specific to engineered T cells expressing hdCK3mut, we compared the signal from animals receiving only the hdCK3mut PET reporter to that in the F5/hdCK3mut recipients (Figure 7C; Supplemental Figure 5, A and C; Supplemental Figure 6, C and D; and Supplemental Table 1).

Applying hdCK3mut PET reporter imaging allowed for the detection of engineered tumor-infiltrating lymphocytes in M202 tumors. The control nontransduced cohort had equivalent signal (fold change in signal of tumor compared to muscle with maximum %ID/g) in both M202 and M207 tumors, verifying that the tumor cell lines have equivalently low nonspecific accumulation of [18F]-L-FMAU. Quantification of the [18F]-L-FMAU PET scan determined that the M202 signal was highest in F5/hdCK3mut animals in comparison to M202 signal in hdCK3mut animals alone (P < 0.005) (Figure 7D and Supplemental Figure 6D). Both F5/hdCK3mut and hdCK3mut groups had increased [18F]-L-FMAU signal in HLA-matched tumors (M202) compared with that in HLA-mismatched tumors (M207). The increase in signal from M202 tumors of hdCK3mut animals suggests that immune cells will traffic to HLA-matched tumors, even when cells are not engineered toward a specific cancer antigen.

F5/hdCK3mut recipients had 2-fold higher accumulation of [18F]-L-FMAU in the M202 tumors compared with that in the matched M207 tumors. The mean difference in signal was 0.44 between M202 and M207 tumors, and in 11 of 11 animals, the signal in M202 tumors was higher than that in M207 tumors (Supplemental Table 1). This allowed for visualization by PET reporter imaging of engineered T cells homing to the HLA-matched tumor (Figure 7D and Supplemental Figure 6D).

**Discussion**

Our work demonstrates that hdCK3mut and [18F]-L-FMAU are an appropriate PET reporter gene and probe combination for monitoring the presence of engineered lymphocytes in HLA-matched tumors. The expression of hdCK3mut in this model did not alter T cell function or development or cause a nonspecific activation of T cells when evaluated by both in vitro and in vivo assays. hdCK3mut PET reporter imaging is a safe and effective method for monitoring ACTs.

**PET reporter imaging can be applied to current cell-based therapies.** The improved sensitivity of hdCK3mut in detecting small infiltrating populations can be a valuable tool for preclinical and clinical studies investigating the locations of all engineered cells. As novel TCRs and CARs are developed to target additional cancer antigens, the capacity to serially monitor the location and potentially circumvent complications of off-target engineered cell locations is essential. This can provide information on cell locations prior to the detection of complications (16, 36). hdCK3mut
CURRENT ACTs have relied on the infusion of expanded lymphocytes (1, 5, 10, 38), with limited methods for follow-up measurements outside of peripheral blood. The addition of a PET reporter can help evaluate whether the loss of engineered cells in the peripheral blood correlates with decreased T cells within the tumor or if the quantity of cells is exclusive and cytotoxic T cells remain within sites beyond the circulation (41). Serial scans can monitor the decline in total infiltrated cell numbers over time, providing a noninvasive method for kinetic measurements of the engineered immunotherapy.

In addition, reporter gene imaging is more appropriate for long-term sequential tracking of immunotherapies than alternative imaging strategies, such as ex vivo labeling of cells. Current preclinical methods have used $^{64}$Cu for direct cell labeling, which caused significant double-strand DNA breaks, a reduction in IFN-$\gamma$ production, and, at high enough doses, an effect on cell survival (42, 43). The half-life of these positron-emitting radiometals ($^{64}$Cu: 12.7 hours, $^{89}$Zr: 3.3 days) will limit imaging to a maximum of 1 week after transfusion (4 days for $^{64}$Cu). Additionally, due to the extended half-life of the directly labeled cells, no other PET imaging, such as [$^{18}$F]-FDG, can be performed.

In our model system, we detected quantifiable signal with cells at an estimated density of less than 0.5% within tumors based on previous work (32). In clinical settings, the density of hdCK3-mut cells in vivo may be substantially higher after bulk infusion of engineered T cells, with previous clinical trials infusing from $1 \times 10^5$ up to $130 \times 10^9$ (5, 8, 10, 38). In some cases, this number was calculated based on the number of cells that were successfully transduced detected by flow cytometry of the transgenic TCR or CAR, giving patients an even higher total cell dose. When calculated as engineered T cells per kilogram, our short-term ACT gave approximately $1.25 \times 10^8$ cells per kilogram. Clinical protocols have given cells in the range of $1 \times 10^5$ cells per kilogram up to $2 \times 10^5$ cells per kilogram (9, 10). Our cell dosing was within range of clinical applications, and we were able to detect signal within the M202 tumors of F5/hdCK3mut recipients, demonstrating that our PET reporter imaging should be directly scalable to clinical applications. For therapies with increased quantities of cells, this will increase the reporter signal, allowing for a better signal-to-noise ratio in the [$^{18}$F]-L-FMAU PET scan (39, 40). This is important in detecting the correct homing capacity as well as the potential off-target locations of hdCK3mut-expressing cells.

Current ACTs have relied on the infusion of expanded lymphocytes (1, 5, 8, 10, 38), with limited methods for follow-up measurements outside of peripheral blood. The addition of a PET reporter can help evaluate whether the loss of engineered cells in the peripheral blood correlates with decreased T cells within the tumor or if the quantity of cells is exclusive and cytotoxic T cells remain within sites beyond the circulation (41). Serial scans can monitor the decline in total infiltrated cell numbers over time, providing a noninvasive method for kinetic measurements of the engineered immunotherapy.

In addition, reporter gene imaging is more appropriate for long-term sequential tracking of immunotherapies than alternative imaging strategies, such as ex vivo labeling of cells. Current preclinical methods have used $^{64}$Cu for direct cell labeling, which caused significant double-strand DNA breaks, a reduction in IFN-$\gamma$ production, and, at high enough doses, an effect on cell survival (42, 43). The half-life of these positron-emitting radiometals ($^{64}$Cu: 12.7 hours, $^{89}$Zr: 3.3 days) will limit imaging to a maximum of 1 week after transfusion (4 days for $^{64}$Cu). Additionally, due to the extended half-life of the directly labeled cells, no other PET imaging, such as [$^{18}$F]-FDG, can be performed. [$^{18}$F]-L-FMAU uses the $^{18}$F isotope, which has greater than 97% positron emission, with limited dangerous $\alpha$ or $\gamma$ emissions. The short half-life of $^{18}$F (110 minutes) also limits the exposure, and radiation is undetectable within 12 to 24 hours (44, 45). For in vivo scans, only a fraction of the dose is accumulated or exposed to the lymphocytes in comparison to prelabeling, which incu-
bates radiosensitive lymphocytes with high doses of probe. By using a PET reporter gene, sequential, noninvasive imaging can be obtained at any time point. The use of a reporter-specific \(^{18}F\) probe also allows for alternate probes to be scanned within 24 hours, as seen in Figures 2 and 7.

**Methods to further enhance the sensitivity or specificity of hdCK3mut PET reporter detection.** hdCK3mut was demonstrated to be approximately 2-fold more sensitive in a comparison study between alternate PET reporter genes (26). It has been noted that the gene transfer mechanism (retro- or lentivirus) as well as the promoter can alter the efficacy of the PET reporter genes (26). Using optimized vectors and promoters should reduce potential silencing and improve the sensitivity of hdCK3mut reporter imaging. Alternatively, future PET reporter applications could use lineage-specific promoters to track a subset of cells. This could be applied to HSC transplants that currently will have all transduced cells expressing the PET reporter, including B and myeloid cells, but only CD3 cells expressing the engineered TCR. Applying a lineage-specific reporter could reduce the potential nonspecific signal in tumors and organs seen from reporter-labeled myeloid and B cells. The metabolic state of the reporter-labeled cells may also change the total accumulation of the PET reporter probe, due to differences in active and quiescent cell populations (39). Future studies will investigate whether changes in cell cycle or metabolism alter the PET reporter function in vivo.

**Model limitations of BLT mice in T cell development.** The T cells developed within this model do not contain a full T cell repertoire and can have variable T cell development, including low total number of cells, and therefore may not fully depict what will be seen in human patients (34). The establishment of a non-transduced thymic graft helps to recapitulate the clinical settings in which patients are not tolerized prior to infusion of the PET reporter gene. In vitro and in vivo T cell activation experiments demonstrate the functionality of cells expressing hdCK3mut. Further optimization in the model system may increase the total T cell quantity, but importantly, the expression of hdCK3mut was not deleterious and did not hinder or alter total output.

Concluding remarks. Previous studies have evaluated the expression of a human PET reporter for short-term (6 hours after infusion) T cell trafficking (46). We demonstrate hdCK3mut PET reporter imaging in two models of ACT: short-term infusion of engineered PBMCs and a stem cell–based therapy. To date, this is the first study to our knowledge to show that a human PET reporter gene can simultaneously monitor engraftment and tumor infiltration without altering T cell development and function. hdCK3mut can be broadly applicable for monitoring all cell-based therapies and provides the necessary tool for the tracking of cellular immunotherapies.

**Methods**

**Mice.** Immune-deficient NSG mice were bred and maintained according to the guidelines of the Department of Laboratory Animal Medicine (DLAM) at UCLA. All animal studies were carried out by using protocols that had been approved by DLAM at UCLA.

**Human BLT establishment.** Mice were generated as previously described (32). Four months after the generation of humanized BLT mice, the mice were then irradiated at 3 Gy using a cobalt-60 source to remove endogenous cells. Then, the frozen transduced CD34 cells were thawed and injected. Tumors were then implanted at 12 weeks after HSC transplant, and animals were imaged 4 weeks after the tumor implantation.

**Construction of hdCK3mut-expressing retro- and lentiviral vectors.** The lentiviral vector pF5-sr39tk expressing the F5 TCR chains and the sr39tk reporter was constructed as previously described (32). The TCR and sr39tk were removed, and hdCK3mut-IRES-YFP (20) was inserted. The lentiviral vector containing the MSCV promoter and F5 TCR and sr39tk (from Richard Koya, UCLA) was used to establish the F5/hdCK3mut vector. sr39tk was replaced with hdCK3mut. The TCR chains and the reporter gene are separated by picornaviral-derived 2A sequences that allow the expression of a polycistronic mRNA and the generation of the 3 protein products. Lentiviral vector stocks were produced by transfection of 293T cells with the lentiviral construct and the helper plasmids VSVG, PMDL, and pREV. The MSCV hdCK3mut-IRES-YFP retrovirus construct used was previously described (20), and an MSGV vector containing
hdCK3mut, tEGFR (gift from Stephen Forman and Christine Brown, City of Hope National Medical Center, Duarte, California, USA), and codon-optimized F5 TCR was made in-house. Retroviral stocks were produced by transient transfection of 293T cells with the retroviral construct and packaged with RD114 or GalV coat. A stable virus-producing cell line, PG13, produced the MSCV-driven retrovirus with codon-optimized F5 TCR alone (gift from Antoni Ribas, UCLA).

Transduction of human HSCs. Fresh human fetal liver was obtained from Advanced Bioscience Resources Inc. The tissue was processed, and CD34 cells were purified as previously described and were transduced (multiplicity of infection = 5) using RetroNectin (Clontech) (32). Cells were then washed and frozen for CD34 cell injections.

Transduction of human PBMCs. PBMCs derived from anonymized donors were obtained from CFAR Virology Core. HLA-A02 PBMCs were thawed onto plates coated with anti-CD3 (OKT3) with 1 μg/ml anti-CD28 (CD28.2) in RPMI, 5% heat-inactivated FBS, HEPES, BME, and 600 IU/ml IL-2 (PeproTech) for 48 hours. PBMCs were then spininfected at 1,450 g for 90 minutes, 30°C, on days 3 and 4 with virus. PBMCs were washed and placed at 1 × 10^6 cells per milliliter in RPMI, 5% heat-inactivated FBS, HEPES, BME, and 600 IU/ml IL-2 and expanded for 72 hours. Infection efficiency was determined by FACS.

Immunohistochemistry. Tissue was fixed in 10% phosphate-buffered formalin overnight. Sections were cut at 0.4 micron, with staining for H&E for representative histology every 5 slides. Tissue sections were heated at 65°C for 1 hour to melt the paraffin, followed by rehydration. Antigen retrieval was performed using citric acid buffer (pH 6) or Tris/EDTA (pH 9) and visualization was performed using the Liquid DAB+ Kit (DAKO). Slides were blocked for endogenous peroxidase activity with 3% H₂O₂ in PBS for 5 minutes, then blocked with 2.5% normal horse serum (Vector Labs). Primary antibodies were diluted with 2.5% normal horse serum as follows: anti-CD3 (AbCam ab828, 1:50), anti-CD8 (eBiosciences C8/144B, 5 μg/ml) and incubated at 4°C overnight, before secondary antibody was added (ImmPRESS Anti-Mouse or Anti-Rabbit Ig [peroxidase] Polymer Detection Kit, Vector Labs).

Flow cytometry and FACS. Single-cell suspensions from spleen and peripheral blood were stained with the following fluorochrome-conjugated antibodies: MART-1 tetramer (MBL), with eBiosciences antibodies for anti-hCD45 (2D1), anti-hCD4 (RPA-T4), anti-hCD8 (SK1), anti-hCD3 (OKT3), anti-hCD33 (HIM3-4), anti-hCD56 (CMSB), anti-hCD123 (6H6), anti-hCD19 (HIB19), IgG isotype (P3.6.2.8.1), and anti-IFN-γ (4S.83). Flow cytometry was performed on the BD FACS Canto II or BD FACS Aria. Additional antibodies used for flow cytometry analysis of activation and cytotoxicity include eBiosciences CD69 (FN50), CD71 (OKT9), CD25 (BD Biosciences M-A251), and MART-1 dextramer (Immudex).

MicroPET and image analysis. BLT mice were imaged 4 weeks after tumor challenge and 16 weeks after HSC transplant. NSG mice given transduced PBMCs were imaged 3 weeks after tumor implantation at days 1, 2, and 8 after ACT. Mice were then euthanized under gas anesthesia (2% isoflurane) and injected i.v. with 200 μCi of either [³¹F]-FDG or [³¹F]-L-FMAU (radiochemical synthesis described in ref. 37), followed by 1 hour unconscious uptake. Mice were then positioned in an imaging chamber for sequential imaging with the Siemens Preclinical Solutions MicroPET Focus 220 and MicroCAT II CT systems (Siemens). MicroPET data were acquired for 10 minutes and reconstructed with a filtered background projection probability algorithm. MicroPET and CT images were coregistered. Quantification of PET signal was performed by drawing 3D ROIs around the area of interest using AMIDE software (http://amide.sourceforge.net/). The maximum intensity of the ROI, based on the %ID/g, was normalized to control muscle of the left hamstring. Data are presented as fold change over muscle. Images are presented here using a false-color scale that is proportional to tissue concentration (%ID/g) of positron-labeled probe. Red represents the highest, with yellow, green, and blue corresponding to lower concentrations.

Cell line. The human melanoma cell lines M202, M207, and M407 were used (gifts from Antoni Ribas, UCLA). M202 is HLA-A*0201/MART⁺, M207 is HLA-A*0201/MART⁺, M407 is HLA-A*0201/MART⁺. Both M202 and M207 cell lines express the MART-1 antigen. Cell lines were cultured in complete serum media containing RPMI 1640 with L-glutamine, with 10% (all percentages represent v/v) fetal bovine serum and 1% penicillin and streptomycin at 37°C with 5% CO₂. K562 aAPCs were transduced with HLA-A*0201 and CD80 under neomycin selection (gift from Antoni Ribas, UCLA). K562-HLA-A*0201 cells were then transduced with MART-IRES-YFP, hdCK3mut-IRES-YFP, or YFP alone. K562 aAPCs were maintained in RPMI, 10% FBS, penicillin and streptomycin, L-glutamine, and G418.

Xenografts. Confluent plates of M202, M207, and M407 cells were trypsinized and counted. 5 × 10⁶ cells per xenograft were implanted subcutaneously on the flank of BLT humanized or NSG mice in 100 μl total volume, with a 50% Matrigel, 50% DEMEM mixture. M202 cells were placed on the left side and M207 or M407 cells were implanted on the right side of all animals (32).

In vitro stimulation and activation with aAPCs. Spleens were harvested and homogenized into single cells through a 40-micron filter in RPMI, 5% FBS media, followed by rbc lysis for 5 minutes at room temperature. Cells were then resuspended in RPMI, 5% heat-inactivated FBS, HEPES, BME, and 600 IU/ml IL-2 (PeproTech). Cultures were monitored for 3 days, with media supplementation as needed. On day 4, cells were counted and cocultured with aAPCs or alone. Cocultures with aAPCs were incubated for 72 hours after plating. Lymphocytes plated alone were incubated with 1× cell stimulation cocktail (eBiosciences) (PMA/ionomycin) overnight, with Golgiplug (BD Biosciences) added 6 hours prior to analysis. Cells were then harvested, fixed, and permeabilized (BD Biosciences Cytofix/Cytoperm), and flow cytometry was used to determine intracellular IFN-γ levels. Transduced PBMCs were subjected to both coculture and cell stimulation after 72 to 96 hours after infection.

Repeated aAPC coculture with engineered PBMCs. PBMCs were thawed, stimulated, and infected. After 48 hours, infection efficiency was checked (day 0) and cells were plated at a density of 1 × 10⁶ cells per milliliter in T cell media with a 5:1 ratio of T cells/aAPCs. Day 2 cell count and analysis was obtained. On days 5, 9, 12, and 15, the total cell counts, FACS analysis, and replating with freshly irradiated aAPCs were performed.

Cytotoxicity. Melanoma cell lines (M202, M207, and M407) (1 × 10⁶ cells per milliliter) were labeled with a green fluorescent membrane dye, DiOC18 (Life Technologies), in serum-free media at 37°C according to the manufacturer’s recommendations. Cells were washed with PBS and then media and mixed with effector PBMCs (untransduced, F5, F5/hdCK3mut, hdCK3mut/YFP) at an effector/
target ratio of 10:1. In a 48-well plate, 1 × 10^6 GFP melanoma cells were placed with 1 × 10^6 PBMCs and incubated overnight at 37°C. The total culture was collected and stained for CD45 (Ebioscience 2D1), CD3 (Ebioscience OKT3), CD8 (Ebioscience SK1), CD25 (BD Biosciences MA251), CD71 (Ebioscience OKT9), and MART-1 dextramer (Immudex) for PBMC activation. DAPI was added to measure cell death. Cell cytotoxicity was measured as a percentage of DiOC18' DAPI' cells. Percentage cytotoxicity was to the percentage of cytotoxicity in untransduced PBMCs.

Short-term ACT. Transduced PBMCs were restimulated on plates coated with anti-CD3 (OKT3) 24 hours prior to implantation. Relative infection efficiency was approximately 40% in both cohorts of animals. On day 0, animals received 5 × 10^6 PBMCs i.v., with 50,000 IU IL-2 i.p. (PeproTech). [^F]-L-FAU imaging was performed on days 1 and 8. [^F]-FDG imaging was performed on day 2. Animals were sacrificed on day 9 for FACS and histology of tumors.

Statistics. Graphs are plotted as mean with SEM or SD for error bars. Statistics were analyzed using 1-way ANOVA, followed by Dunnett’s or Tukey’s secondary multiple-comparison test, 2-way ANOVA with Tukey’s secondary multiple-comparison test, or a 2-tailed Stu- neet’s or Tukey’s secondary multiple-comparison test, 2-way ANOVA bars. Statistics were analyzed using 1-way ANOVA, followed by Dun-

Acknowledgments

We would like to thank the UCLA Crump Institute for Molecular Imaging and technical staff; Mark Lazari and Sam Sedeghi for radiochemistry; the UCLA AIDS Institute and Center for AIDS Research (5P30 AI028697) cores for the supply of fetal tissue, human PBMCs, and the generation of humanized mice; Roger Hollis for help with virus preparation; and Donghui Cheng and Colleen Mathis for help with FACS and sample preparation. M.N. McCracken was supported by the California Institute for Regenerative Medicine training grant (TG2-01169) and the UCLA In Vivo Cellular and Molecular Imaging Center Career Development Award (P50 CA086306). This work was supported by the California Institute for Regenerative Medicine Tools/Technology Award (RT1-01126), the NanoSystems Biology Cancer Center (US4 CA151819), and NIH/NCI/CalTech Prime (P01 CA132681). O.N. Witte is an investigator of the Howard Hughes Medical Institute and partially supported by the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.

Address correspondence to: Owen N. Witte, University of California, Los Angeles, 675 Charles E. Young Dr. South, 5-748 MRL, Los Angeles, California 90095-1662, USA. Phone: 310.206.0386; E-mail: OwenWitte@mednet.ucla.edu.


41. The Journal of Clinical Investigation


